Update on New and Emerging Treatments for Schizophrenia.

Ganesh Gopalakrishna, Muaid H Ithman, John Lauriello

Journal: The Psychiatric clinics of North America 2017;39(2):217-38

PMID: 27216901

Full Text on Elsevier Science View on PubMed

Abstract

Although there has been more than 50 years of development, there remains a great need for better antipsychotic medications. This article looks at the recent advances in treatment of schizophrenia. New hypotheses have been suggested that may replace or complement the dopamine hypotheses. The article explores the different novel drugs that impact some of the key neurotransmitter systems currently. Phosphodiesterase 10A inhibitors and α-7 neuronal nicotinic acetylcholine receptor modulators constitute the majority. The marketing of these medications eventually may result in change about how schizophrenia is treated.

Address: Department of Psychiatry, University of Missouri-Columbia, One Hospital Drive, Columbia, MO 65212, USA. Electronic address: [email protected].; Department of Psychiatry, University of Missouri-Columbia, One Hospital Drive, Columbia, MO 65212, USA.

DOI: 10.1016/j.psc.2016.01.005

Link outs

Free resources

Medical:

https://medlineplus.gov/schizophrenia.html

Other Literature Sources:

https://scite.ai/reports/27216901

Subscription / membership required

Full Text Sources:

MeSH Terms: Antipsychotic Agents, Drug Approval, Excitatory Amino Acid Agents, Glycine Agents, Humans, Minocycline, Nicotinic Agonists, Phosphodiesterase Inhibitors, Piperazines, Piperidines, Schizophrenia